Q2 2026 Guardant Health Inc Earnings Call Transcript
Key Points
- Guardant Health Inc (GH) delivered a landmark quarter with FDA approval for Guardant360 Liquid CDx and a higher-throughput, lower-cost Shield workflow, reinforcing its leadership in liquid biopsy.
- Revenue grew 44% year-over-year to $335 million, with strong broad-based growth across oncology (38%), biopharma/data (9%), and screening (253%).
- Shield achieved major milestones: inclusion in American Cancer Society (ACS) colorectal cancer screening guidelines and a coverage decision from UnitedHealth Group, expanding access to ~70 million lives (60% of the market).
- Oncology volumes surged 63% year-over-year, driven by Guardant360 Liquid (>30% growth), Guardant360 Tissue (accelerating), and Reveal (>100% growth), with therapy monitoring emerging as a key growth driver.
- The company raised full-year 2026 revenue guidance to $1.34-$1.36 billion (36-38% growth) and expects Shield cost per test to drop ~15% by end of 2026, supporting margin expansion.
- Biopharma and data business hit a record $61 million in revenue, with 28 companion diagnostic approvals and new collaborations (e.g., Nuvalent), highlighting the strategic value of the platform.
- Guardant Health Inc (GH) remains on track for ADLT designation for Guardant360 Liquid CDx in H1 2027, which could significantly boost ASPs and profitability.
- The company is committed to cash flow breakeven by end of 2027, with the non-screening business already generating positive cash flow.
- Adjusted EBITDA loss widened to $56 million in Q2 2026, and free cash flow burn increased to $70 million due to higher CapEx for screening lab automation.
- Screening revenue growth is heavily dependent on reimbursement; commercial ASPs are expected to decline as the mix of commercially insured patients under 65 increases, pressuring near-term pricing.
- The phased rollout of Guardant360 Liquid CDx and the wait for ADLT designation (H1 2027) limit immediate revenue upside from the FDA approval.
- Reveal reimbursement submissions to MolDx for breast cancer surveillance, immuno-oncology, and chemotherapy monitoring are progressing slower than expected, with no definitive timeline for approval.
- The company faces tough year-over-year comps in Q3 and Q4 for Guardant360 volumes, and management cautions that Q2's exceptional Shield growth may not be sustainable sequentially.
- UnitedHealth coverage is a win, but pricing negotiations are ongoing, and the company does not expect major additional payer wins in the near term, limiting immediate commercial expansion.
- Shield's multi-cancer detection report requires patient authorization for medical records, which may limit data collection and adoption in some cases.
- The company's heavy investment in commercial infrastructure (sales force, DTC, Quest collaboration) is driving operating expenses up 34% year-over-year, pressuring near-term profitability.
Hello, everyone. Thank you for joining us, and welcome to the Guardant Health second-quarter 2026 earnings call. (Operator Instructions)
I will now hand the conference over to Zarak Khurshid, VP of Investor Relations. Zarak, please go ahead.
Thank you. Earlier today, Guardant Health released financial results for the quarter ended June 30, 2026. Joining me today from Guardant are Co-CEOs, Helmy Eltoukhy; and AmirAli Talasaz; and Chief Financial Officer, Mike Bell.
Before we begin, I'd like to remind you that during this call, we will be making forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated.
This call will also include a discussion of non-GAAP financial measures, which are adjusted to exclude certain specified items. Additional information regarding material risks and uncertainties as well as
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
